{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:07:27Z","timestamp":1762013247036,"version":"build-2065373602"},"reference-count":56,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2020,2,13]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Primary aldosteronism is one of the most common causes of secondary\nhypertension. Patients with this endocrine syndrome are at increased cardiovascular risk, higher\nthan hypertensive individuals with equal blood pressure levels.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The study aimed to thoroughly present and critically discuss the novel insights into the\nfield of primary aldosteronism, focusing on the clinically meaningful aspects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>We meticulously evaluated existing data in the field of primary aldosteronism in order to\nsummarize future perspectives in this narrative review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Novel data suggests that a subclinical form of primary aldosteronism might exist. Interesting\nfindings might simplify the diagnostic procedure of the disease, especially for the localization of\nprimary aldosteronism. The most promising progress has been noted in the field of the molecular\nbasis of the disease, suggesting new potential therapeutic targets.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Several significant aspects are at early stages of evaluation. Future research is essential\nto investigate these well-promising perspectives.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573402115666190415155512","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T15:31:28Z","timestamp":1555428688000},"page":"19-23","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Primary Aldosteronism: Novel Insights"],"prefix":"10.2174","volume":"16","author":[{"given":"Konstantinos","family":"Stavropoulos","sequence":"first","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Imprialos","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Papademetriou","sequence":"additional","affiliation":[{"name":"VAMC and Georgetown University, Washington, DC, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[{"name":"VAMC and George Washington University, Washington, DC, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"1st Cardiology Department, Kapodestrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriakos","family":"Dimitriadis","sequence":"additional","affiliation":[{"name":"1st Cardiology Department, Kapodestrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/236239","volume":"2011:","author":"Faselis C.","year":"2011","unstructured":"Faselis C.; Doumas M.; Papademetriou V.; Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011,2011:","journal-title":"Int J Hypertens"},{"key":"ref=2","first-page":"3","volume":"45","author":"Conn J.W.","year":"1955","unstructured":"Conn J.W.; Part I.; Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955,45,3-17","journal-title":"J Lab Clin Med"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"Mulatero P.","year":"2004","unstructured":"Mulatero P.; Stowasser M.; Loh K.C.; Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004,89,1045-1050","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"Funder J.W.","year":"2016","unstructured":"Funder J.W.; Carey R.M.; Mantero F.; The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016,101,1889-1916","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"Rossi G.P.","year":"2006","unstructured":"Rossi G.P.; Bernini G.; Caliumi C.; A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006,48,2293-2300","journal-title":"J Am Coll Cardiol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","volume":"371","author":"Douma S.","year":"2008","unstructured":"Douma S.; Petidis K.; Doumas M.; Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet 2008,371,1921-1926","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005574","volume":"6","author":"Maiolino G.","year":"2017","unstructured":"Maiolino G.; Rossitto G.; Bisogni V.; Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) study. J Am Heart Assoc 2017,6(: pii:)","journal-title":"J Am Heart Assoc"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"Monticone S.","year":"2017","unstructured":"Monticone S.; Burrello J.; Tizzani D.; Prevalence and clinical manifestations of primary aldosteronism encountered in Primary Care Practice. J Am Coll Cardiol 2017,69,1811-1820","journal-title":"J Am Coll Cardiol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"K\u00e4yser S.C.","year":"2016","unstructured":"K\u00e4yser S.C.; Dekkers T.; Groenewoud H.J.; Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016,101,2826-2835","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051032","volume":"18","author":"Funder J.W.","year":"2017","unstructured":"Funder J.W.; Aldosterone and mineralocorticoid receptors-physiology and pathophysiology. Int J Mol Sci 2017,18","journal-title":"Int J Mol Sci"},{"key":"ref=11","first-page":"26","author":"Doumas M.","year":"2016","unstructured":"Doumas M.; Douma S.;  Interventional Therapies for Secondary and Essential Hypertension, Updates in Hypertension and Cardiovascular Protection In: Tsioufis C, Schmieder R, Mancia G, eds. 2016,26-55","journal-title":"Interventional Therapies for Secondary and Essential Hypertension, Updates in Hypertension and Cardiovascular Protection"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"Savard S.","year":"2013","unstructured":"Savard S.; Amar L.; Plouin P.F.; Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013,62,331-336","journal-title":"Hypertension"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"Monticone S.","year":"2018","unstructured":"Monticone S.; D\u2019Ascenzo F.; Moretti C.; Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018,6,41-50","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams B.","year":"2018","unstructured":"Williams B.; Mancia G.; Spiering W.; 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018,36,1953-2041","journal-title":"J Hypertens"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11154-011-9159-3","volume":"12","author":"Karagiannis A.","year":"2011","unstructured":"Karagiannis A.; Treatment of primary aldosteronism: Where are we now? Rev Endocr Metab Disord 2011,12,15-20","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/HJH.0000000000001642","volume":"36","author":"Stavropoulos K.","year":"2018","unstructured":"Stavropoulos K.; Imprialos K.P.; Doumas M.; Subclinical target organ damage in primary aldosteronism: Resistant to spironolactone therapy? J Hypertens 2018,36,701","journal-title":"J Hypertens"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1677\/ERC-08-0094","volume":"15","author":"Karagiannis A.","year":"2008","unstructured":"Karagiannis A.; Tziomalos K.; Kakafika A.I.; Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocr Relat Cancer 2008,15,693-700","journal-title":"Endocr Relat Cancer"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"Williams T.A.","year":"2017","unstructured":"Williams T.A.; Lenders J.W.M.; Mulatero P.; Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Endocrinol 2017,5,689-699","journal-title":"Lancet Endocrinol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/hr.2010.166","volume":"34","author":"Ito Y.","year":"2011","unstructured":"Ito Y.; Takeda R.; Karashima S.; Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011,34,98-102","journal-title":"Hypertens Res"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/hr.2010.206","volume":"34","author":"Rossi G.P.","year":"2011","unstructured":"Rossi G.P.; Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it? Hypertens Res 2011,34,43-46","journal-title":"Hypertens Res"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190311130138","author":"Stavropoulos K.","year":"2019","unstructured":"Stavropoulos K.; Papadopoulos C.; Koutsampasopoulos K.; Mineralocorticoid receptor antagonists in the management of primary aldosteronism. Curr Pharm Des [Epub ahead of print].2019","journal-title":"Curr Pharm Des"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","volume":"167","author":"Brown J.M.","year":"2017","unstructured":"Brown J.M.; Robinson-Cohen C.; Luque-Fernandez M.A.; The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 2017,167,630-641","journal-title":"Ann Intern Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","volume":"175","author":"Fassnacht M.","year":"2016","unstructured":"Fassnacht M.; Arlt W.; Bancos I.; Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016,175,G1-G34","journal-title":"Eur J Endocrinol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jch.13039","volume":"19","author":"Stavropoulos K.","year":"2017","unstructured":"Stavropoulos K.; Imprialos K.P.; Doumas M.; Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients? J Clin Hypertens (Greenwich) 2017,19,798-800","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=25","first-page":"149","volume":"1","author":"Wolley M.J.","year":"2017","unstructured":"Wolley M.J.; Stowasser M.; New advances in the diagnostic workup of primary aldosteronism. J Endocr Soc 2017,1,149-161","journal-title":"J Endocr Soc"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/jch.12521","volume":"17","author":"Doumas M.","year":"2015","unstructured":"Doumas M.; Athyros V.; Papademetriou V.; Screening for primary aldosteronism: Whom and how? J Clin Hypertens (Greenwich) 2015,17,547-548","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jch.13291","volume":"20","author":"Stavropoulos K.","year":"2018","unstructured":"Stavropoulos K.; Imprialos K.P.; Katsiki N.; Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone? J Clin Hypertens (Greenwich) 2018,20,942-948","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton P.K.","year":"2018","unstructured":"Whelton P.K.; Carey R.M.; Aronow W.S.; 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018,71,e127-e248","journal-title":"J Am Coll Cardiol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jch.13041","volume":"19","author":"Tirosh A.","year":"2017","unstructured":"Tirosh A.; Hannah-Shmouni F.; Lyssikatos C.; Obesity and the diagnostic accuracy for primary aldosteronism. J Clin Hypertens (Greenwich) 2017,19,790-797","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jch.12523","volume":"17","author":"Rye P.","year":"2015","unstructured":"Rye P.; So B.; Harvey A.; Unadjusted plasma renin activity as a \u2018first look\u2019 test to decide upon further investigations for primary aldosteronism. J Clin Hypertens (Greenwich) 2015,17,541-546","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2014-1153","volume":"99","author":"Ahmed A.H.","year":"2014","unstructured":"Ahmed A.H.; Cowley D.; Wolley M.; Seated saline suppression testing for the diagnosis of primary aldosteronism: A preliminary study. J Clin Endocrinol Metab 2014,99,2745-2753","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1055\/s-0035-1565182","volume":"47","author":"Funder J.W.","year":"2015","unstructured":"Funder J.W.; Primary aldosteronism: New answers, new questions. Horm Metab Res 2015,47,935-940","journal-title":"Horm Metab Res"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1365-2362.2011.02531.x","volume":"41","author":"Gouli A.","year":"2011","unstructured":"Gouli A.; Kaltsas G.; Tzonou A.; High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011,41,1227-1236","journal-title":"Eur J Clin Invest"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1210\/jc.2015-1268","volume":"100","author":"Markou A.","year":"2015","unstructured":"Markou A.; Sertedak A.; Kaltsas G.; Stress-induced aldosterone hypersecretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015,100,2857-2864","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.113.02097","volume":"63","author":"Rossi G.D.","year":"2014","unstructured":"Rossi G.D.; Auchus R.J.; Brown M.; An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014,63,151-160","journal-title":"Hypertension"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.09295","volume":"71","author":"Rossi G.P.","year":"2018","unstructured":"Rossi G.P.; Funder J.W.; Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: Pro side of the argument. Hypertension 2018,71,5-9","journal-title":"Hypertension"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MED.0000000000000407","volume":"25","author":"Rossi G.P.","year":"2018","unstructured":"Rossi G.P.; Update in adrenal venous sampling for primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 2018,25,160-171","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.surg.2004.06.051","volume":"136","author":"Young W.F.","year":"2004","unstructured":"Young W.F.; Stanson A.W.; Thompson G.B.; Role for adrenal venous sampling in ptimary aldosteronism. Surgery 2004,136,1227-1235","journal-title":"Surgery"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1148\/rg.274065150","volume":"27","author":"Patel S.M.","year":"2007","unstructured":"Patel S.M.; Lingam R.K.; Beaconsfield T.I.; Role of radiology in the management of primary aldosteronism. Radiographics 2007,27,1145-1157","journal-title":"Radiographics"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-151-5-200909010-00007","volume":"151","author":"Kempers M.J.","year":"2009","unstructured":"Kempers M.J.; Lenders J.W.; van Outheusden L.; Systematic review: Diagnostic procedure to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009,151,329-337","journal-title":"Ann Intern Med"},{"key":"ref=41","first-page":"414","volume":"39","author":"Raman S.P.","year":"2015","unstructured":"Raman S.P.; Lessne M.; Kawamoto S.; Diagnostic performance of multidetector computed tomography in distinguishing unilateral from bilateral abnormalities in primary hyperaldosteronism: comparison of multidetector computed tomography with adrenal vein sampling. J Comput Assist Tomogr 2015,39,414-418","journal-title":"J Comput Assist Tomogr"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/HYPERTENSIONAHA.117.09294","volume":"71","author":"Deinum J.","year":"2018","unstructured":"Deinum J.; Prejbisz A.; Lenders J.W.M.; Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: Con side of the argument. Hypertension 2018,71,10-14","journal-title":"Hypertension"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/HYPERTENSIONAHA.118.11382","volume":"72","author":"Williams T.A.","year":"2018","unstructured":"Williams T.A.; Burrello J.; Sechi L.A.; Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 2018,72,641-649","journal-title":"Hypertension"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"E1035","DOI":"10.1210\/jc.2013-3789","volume":"99","author":"Riester A.","year":"2014","unstructured":"Riester A.; Fischer E.; Degenhart C.; Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 2014,99,E1035-E1039","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1210\/jc.2007-2055","volume":"93","author":"Mulatero P.","year":"2008","unstructured":"Mulatero P.; Bertello C.; Rossato D.; Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008,93,1366-1371","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1472-6823-14-94","volume":"14","author":"Venos E.S.","year":"2014","unstructured":"Venos E.S.; So B.; Dias V.C.; A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable. BMC Endocr Disord 2014,14,94","journal-title":"BMC Endocr Disord"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cen.12374","volume":"81","author":"Sze W.C.","year":"2014","unstructured":"Sze W.C.; Soh L.M.; Lau J.H.; Diagnosing unilateral primary aldosteronism - comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf) 2014,81,25-30","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1210\/jc.2012-1917","volume":"97","author":"K\u00fcpers E.M.","year":"2012","unstructured":"K\u00fcpers E.M.; Amar L.; Raynaud A.; A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab 2012,97,3530-3537","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1210\/jc.2015-3431","volume":"101","author":"Abe T.","year":"2016","unstructured":"Abe T.; Naruse M.; Young W.F.; A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. J Clin Endocrinol Metab 2016,101,1008-1015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","volume":"71","author":"Heinze B.","year":"2018","unstructured":"Heinze B.; Fuss C.T.; Mulatero P.; Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension 2018,71,317-325","journal-title":"Hypertension"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/HYPERTENSIONAHA.117.10111","volume":"70","author":"Prada E.T.A.","year":"2018","unstructured":"Prada E.T.A.; Burrello J.; Reincke M.; Old and new concepts in the molecular pathogenesis of primary aldosteronism. Hypertension 2018,70,875-881","journal-title":"Hypertension"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrendo.2012.230","volume":"9","author":"Mulatero P.","year":"2013","unstructured":"Mulatero P.; Monticone S.; Rainey W.E.; Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol 2013,9,104-112","journal-title":"Nat Rev Endocrinol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","volume":"127","author":"Scholl U.I.","year":"2017","unstructured":"Scholl U.I.; Abriola L.; Zhang C.; Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma. J Clin Invest 2017,127,2739-2750","journal-title":"J Clin Invest"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","volume":"70","author":"Caroccia B.","year":"2017","unstructured":"Caroccia B.; Prisco S.; Seccia T.M.; Macrolides blunt aldosterone biosynthesis: a proof-of-concept study in KCNJ5 mutated adenoma cells ex vivo. Hypertension 2017,70,1238-1242","journal-title":"Hypertension"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/08037051.2018.1436961","volume":"27","author":"Maiolino G.","year":"2018","unstructured":"Maiolino G.; Ceolotto G.; Battistel M.; Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): Design of a study for personalized diagnosis of primary aldosteronism. Blood Press 2018,27,200-205","journal-title":"Blood Press"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"97128","DOI":"10.1172\/jci.insight.97128","volume":"2","author":"Scortegagna M.","year":"2017","unstructured":"Scortegagna M.; Berthon A.; Settas N.; The E3 ubiquitin ligase Siah1 regulates adrenal gland organization and aldosterone secretion. JCI Insight 2017,2(pii:),97128","journal-title":"JCI Insight"}],"container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T14:34:33Z","timestamp":1583418873000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171631\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402115666190415155512","relation":{},"ISSN":["1573-4021"],"issn-type":[{"type":"print","value":"1573-4021"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}